Market Closed -
NSE India S.E.
12:40:47 16/05/2024 BST
|
5-day change
|
1st Jan Change
|
100.6
INR
|
+1.31%
|
|
+1.06%
|
+0.50%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,094
|
999.2
|
461.3
|
796.7
|
1,599
|
1,050
|
Enterprise Value (EV)
1 |
2,221
|
2,231
|
1,642
|
1,889
|
2,607
|
2,306
|
P/E ratio
|
39.3
x
|
26.4
x
|
-3.78
x
|
16.1
x
|
29.1
x
|
40.8
x
|
Yield
|
1.3%
|
1.42%
|
-
|
1.86%
|
0.93%
|
1.49%
|
Capitalization / Revenue
|
0.52
x
|
0.44
x
|
0.27
x
|
0.32
x
|
0.57
x
|
0.35
x
|
EV / Revenue
|
1.06
x
|
0.99
x
|
0.96
x
|
0.75
x
|
0.93
x
|
0.76
x
|
EV / EBITDA
|
14.5
x
|
13.8
x
|
60.8
x
|
7.74
x
|
11.9
x
|
9.7
x
|
EV / FCF
|
-20.7
x
|
-30.6
x
|
12.7
x
|
29.3
x
|
25.7
x
|
-9.85
x
|
FCF Yield
|
-4.82%
|
-3.27%
|
7.9%
|
3.41%
|
3.89%
|
-10.1%
|
Price to Book
|
1.68
x
|
1.5
x
|
0.88
x
|
1.49
x
|
2.73
x
|
1.65
x
|
Nbr of stocks (in thousands)
|
14,172
|
14,172
|
14,172
|
14,822
|
14,822
|
15,690
|
Reference price
2 |
77.20
|
70.50
|
32.55
|
53.75
|
107.8
|
66.93
|
Announcement Date
|
30/08/18
|
27/08/19
|
04/09/20
|
01/09/21
|
26/08/22
|
30/08/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
2,093
|
2,250
|
1,711
|
2,505
|
2,812
|
3,042
|
EBITDA
1 |
153.4
|
161.9
|
26.99
|
244.3
|
219.8
|
237.8
|
EBIT
1 |
104.6
|
115.7
|
-28.48
|
169.2
|
149.3
|
174.2
|
Operating Margin
|
5%
|
5.14%
|
-1.66%
|
6.75%
|
5.31%
|
5.73%
|
Earnings before Tax (EBT)
1 |
28.83
|
-2.025
|
-136.9
|
41.02
|
91.82
|
47.48
|
Net income
1 |
27.82
|
37.88
|
-122.2
|
47.42
|
56.12
|
25.72
|
Net margin
|
1.33%
|
1.68%
|
-7.14%
|
1.89%
|
2%
|
0.85%
|
EPS
2 |
1.963
|
2.673
|
-8.621
|
3.340
|
3.710
|
1.639
|
Free Cash Flow
1 |
-107.1
|
-72.86
|
129.7
|
64.42
|
101.4
|
-234.1
|
FCF margin
|
-5.12%
|
-3.24%
|
7.58%
|
2.57%
|
3.61%
|
-7.69%
|
FCF Conversion (EBITDA)
|
-
|
-
|
480.73%
|
26.37%
|
46.14%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
135.83%
|
180.73%
|
-
|
Dividend per Share
2 |
1.000
|
1.000
|
-
|
1.000
|
1.000
|
1.000
|
Announcement Date
|
30/08/18
|
27/08/19
|
04/09/20
|
01/09/21
|
26/08/22
|
30/08/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
1,127
|
1,232
|
1,181
|
1,093
|
1,008
|
1,256
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
7.343
x
|
7.607
x
|
43.76
x
|
4.474
x
|
4.586
x
|
5.283
x
|
Free Cash Flow
1 |
-107
|
-72.9
|
130
|
64.4
|
101
|
-234
|
ROE (net income / shareholders' equity)
|
0.63%
|
3.58%
|
-24.4%
|
9.55%
|
10.2%
|
4.29%
|
ROA (Net income/ Total Assets)
|
2.7%
|
2.77%
|
-0.71%
|
4.42%
|
3.73%
|
3.8%
|
Assets
1 |
1,032
|
1,366
|
17,151
|
1,073
|
1,505
|
677.4
|
Book Value Per Share
2 |
45.90
|
47.00
|
37.00
|
36.10
|
39.60
|
40.70
|
Cash Flow per Share
2 |
1.910
|
1.720
|
0.6100
|
0.6900
|
0.7500
|
0.9500
|
Capex
1 |
37.8
|
85.9
|
50.6
|
34.1
|
84.7
|
146
|
Capex / Sales
|
1.81%
|
3.82%
|
2.96%
|
1.36%
|
3.01%
|
4.81%
|
Announcement Date
|
30/08/18
|
27/08/19
|
04/09/20
|
01/09/21
|
26/08/22
|
30/08/23
|
|
1st Jan change
|
Capi.
|
---|
| +32.85% | 709B | | +30.77% | 595B | | -2.40% | 367B | | +20.07% | 334B | | +4.99% | 289B | | +14.34% | 239B | | +9.08% | 211B | | -3.84% | 203B | | +8.76% | 171B |
Other Pharmaceuticals
|